Clinical trial · no report yet · Phase 3

NCT07409272

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

NCT07409272 ↗
Recruiting
Astellas Pharma Global Development, Inc.
Focused

We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Preliminary discovery

Commentary in our index that names this trial so far

Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.

Channel	Found
X threads	2
Bluesky threads	1

The trial

ClinicalTrials.gov

Official title: A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of ASP3082 in Combination With mFOLFIRINOX or NALIRIFOX as First-line Treatment in Participants With KRAS G12D Mutated Metastatic Pancreatic Adenocarcinoma
Phase: Phase 3
Status: Recruiting
Conditions: Pancreatic Cancer; Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarcinoma
Interventions: Setidegrasib; Oxaliplatin; Leucovorin; Irinotecan; fluorouracil; liposomal irinotecan; Placebo
Arms: Setidegrasib plus chemotherapy · Experimental
Placebo plus chemotherapy · Placebo comparator
Enrollment: 614 (estimated)
Primary outcomes: Overall Survival (OS)
Sponsor: Astellas Pharma Global Development, Inc.
Start: Feb 17, 2026
Primary completion: Aug 31, 2029 (estimated)
Results posted: No
Registry record: NCT07409272 · updated Sep 22, 2026